A61P 21 - Drugs for disorders of the muscular or neuromuscular system

Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
11/2002
11/14/2002	US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002	DE10123129A1 Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel Deuterated 3-piperidinopropiophenones and pharmaceutical compositions containing them
11/14/2002	CA2483658A1 Bont/e or snap-25e for treating botulinum toxin a or c1 poisoning and inhibiting muscle contraction
11/14/2002	CA2446795A1 Sulfamide, sulfamate, sulfonamide, urea, amide, alpha, alpha-difluoro amide oxalyl diamide, and heterobicycles fkbp-binding ligands
11/14/2002	CA2446735A1 Substituted cyclohexane-1,4-diamine derivatives with an anti-diarrhoea and peripheral analgesic action
11/14/2002	CA2446365A1 Sulfonamides
11/14/2002	CA2446363A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	CA2435142A1 Kinases and phosphatases
11/13/2002	EP1256578A1 Thiazole derivatives and their use as cdk inhibitors
11/13/2002	EP1255835A2 Polypeptides and nucleic acids encoding same
11/13/2002	EP1255824A2 Non-human transgenic animals for the study of neurodegenerative syndromes
11/13/2002	EP1255755A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
11/13/2002	EP1255726A2 (r)-2-aryl-propionamides, useful in the inhibition of il-8 induced chemiotaxis of neutrophils
11/13/2002	CN1379814A Embryonic or stem-like cell lines produced by cross species nuclear transpcantation and methods for enhancing mebryonic development by genetic alteration of donor cells or by tissue culture conditions
11/13/2002	CN1379772A Substituted indoles for modulating NFKB activity
11/13/2002	CN1379765A Benzodiazepine derivatives usable as parental metabolic glutamate receptor antagonist
11/13/2002	CN1379764A Benzodiazepine derivatives
11/13/2002	CN1379763A Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
11/13/2002	CN1379669A Valdecoxib compositions
11/12/2002	US6479545 Formulation for menopausal women
11/12/2002	CA2009533C Novel cyclosporin galenic forms
11/11/2002	CA2385692A1 Thiazole derivatives
11/07/2002	WO2002088316A2 G-protein coupled receptors
11/07/2002	WO2002088143A2 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
11/07/2002	WO2002088139A1 6h-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
11/07/2002	WO2002088100A2 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
11/07/2002	WO2002088097A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	WO2002088080A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088079A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088078A2 INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES
11/07/2002	WO2002087626A1 Pharmaceutical compositions comprising dendritic cells for immunotherapy of autoimmune disease and treatment methods using the same
11/07/2002	WO2002087593A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
11/07/2002	WO2002087576A1 The treatment of scarring and related conditions using ppar-gamma activators
11/07/2002	WO2002087513A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	WO2002047697A3 Fractions of snake blood, their preparation and use as therapeutic agents
11/07/2002	WO2001093888A3 A method of treatment of amyotrophic lateral sclerosis with a protein extractable from mammalian organs
11/07/2002	WO2001034586A3 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity
11/07/2002	US20020166132 System for regulating in vivo the expression of a transgene by conditional inhibition
11/07/2002	US20020165380 A nucleic acid probe consisting a nucleic acid molecule of at least 15 nucleotides which is complementary to the antisense sequence of a unique fragment of the sequence of a nucleic acid molecule encoding a mammalian fb41 receptor
11/07/2002	US20020165374 Secreted protein HFEAF41
11/07/2002	US20020165275 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/07/2002	US20020165273 Carbamate compounds for use in preventing or treating neurodegenerative disorders
11/07/2002	US20020165268 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
11/07/2002	US20020165230 Gamma-ketoacid dipeptides as inhibitors of caspase-3
11/07/2002	US20020165203 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents
11/07/2002	US20020165186 Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
11/07/2002	US20020164789 Suppressing glial cell activation in central nervous system; obtain mammal with brain disorder, administer modulator of nervous system activity, evaluate for adjusstment in brain disorder
11/07/2002	US20020164738 Cell death inhibitory protein
11/07/2002	US20020164702 Nucleotide sequences coding polypeptide for use in the treatment of muscular disorders
11/07/2002	US20020164682 Mammalian cerberus-like protein and compositions
11/07/2002	US20020164383 Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof
11/07/2002	US20020164349 Induction apoptosis; west nile virus therapy
11/07/2002	US20020164303 Administering nucleic acids to muscle tissue
11/07/2002	CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	CA2445338A1 G-protein coupled receptors
11/07/2002	CA2444882A1 Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
11/07/2002	CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002	CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/06/2002	EP1255112A2 Treatment of T-cell mediated diseases
11/06/2002	EP1254898A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
11/06/2002	EP1254660A2 Methods, kits and compositions for using pyrrole derivatives against anxiety
11/06/2002	EP1254268A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
11/06/2002	EP1254251A2 Neurosteroids as markers for alzheimer's disease
11/06/2002	EP1254242A1 17 human secreted proteins
11/06/2002	EP1254235A2 Drug metabolizing enzymes
11/06/2002	EP1254214A2 Human protein kinases and protein kinase-like enzymes
11/06/2002	EP1254174A2 Human cyr61
11/06/2002	EP1254130A1 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
11/06/2002	EP1254124A1 Dipeptide nitrile cathpsin k inhibitors
11/06/2002	EP1254119A1 Pyrimidine derivatives as selective inhibitors of cox-2
11/06/2002	EP1253932A2 Botulinum toxin pharmaceutical compositions
11/06/2002	EP1253918A2 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
11/06/2002	CN1378544A Substituted azoles compounds
11/06/2002	CN1378541A Inhibitors of c-JUN N-terminal kinase (JNK) and other protein kinases
11/06/2002	CN1378537A 嘧啶衍生物 Pyrimidine derivatives
11/06/2002	CN1378528A Use of carbonylamino derivatives against CNS disorders
11/06/2002	CN1378459A Treatment of auto immune diseases with antagonists which bind to B cell surface markers
11/05/2002	US6476049 1-formyl-n-(2-(4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1 -piperidinyl)) ethyl isonipecotic acid amide or analogs thereof
11/05/2002	US6476029 7-alkyl- and cycloalkyl-substituted imidazotriazinones
11/05/2002	US6476026 Compounds and compositions as protease inhibitors
10/2002
10/31/2002	WO2002086105A1 Delivery of polynucleotide agents to the central nervous sysstem
10/31/2002	WO2002086104A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
10/31/2002	WO2002086069A2 Secreted proteins
10/31/2002	WO2002085945A2 Vhh single heavy chain antibody and a method for its preparation in a mammal
10/31/2002	WO2002085944A2 Single chain camelid vhh antibodies, method for their production in a mammal and their uses
10/31/2002	WO2002085925A2 Melanocortin receptor ligands
10/31/2002	WO2002085910A1 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2- oxopyrrolidin -1 -yl)acetamide
10/31/2002	WO2002085899A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002	WO2002085888A1 Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same
10/31/2002	WO2002085859A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
10/31/2002	WO2002085361A1 Benzimidazolone compounds
10/31/2002	WO2002085357A1 Nociceptin analogs
10/31/2002	WO2002085354A1 Spiroindene and spiroindane compounds
10/31/2002	WO2002085346A1 Use of creatine for the amelioration of oxidative stress
10/31/2002	WO2002068381A3 Aryl-n-cyanoguanidines and methods related thereto
10/31/2002	WO2002066650A3 Streptococcus pyogenes polypeptides and corresponding dna fragments
10/31/2002	WO2002055547A9 Sfrp and peptide motifs that interact with sfrp and methods of their use
10/31/2002	WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002	WO2001044243A3 Novel heteroaryl-diazabicycloalkanes
10/31/2002	WO2000062766A3 Uses of ppar-gamma agonists in neutrophil-induced diseases

1 ... 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 ... 233